Dr. Hui David Shu Cheong - Respiratory Medicine
Highlights
- MCHK RegisteredVerified
- Specialist in Respiratory MedicineBachelor of Medicine and Bachelor of Surgery, UNSW Sydney · Member of the Royal Colleges of Physicians of the United Kingdom · FRCP · Medical degree 1985
- InsuranceBeing compiled|See details
About
Dr. Hui David Shu Cheong is a registered Respiratory Medicine specialist in Hong Kong.
Education
- Bachelor of Medicine and Bachelor of Surgery, UNSW SydneyBachelor of Medicine and Bachelor of Surgery, UNSW Sydney1985
- Member of the Royal Colleges of Physicians of the United KingdomMember of the Royal Colleges of Physicians of the United Kingdom1991
- FRCP1994
- Fellow of the Hong Kong Academy of Medicine (Medicine)Fellow of the Hong Kong Academy of Medicine (Medicine)1998
- FHKCPFellow, Hong Kong College of Physicians1998
Source: Hong Kong Academy of Medicine Fellows Register, checked 12 Sep 2026
Insurance
We're collecting insurance plan data per clinic. For confirmation, contact the clinic directly.
Are you Dr. Hui David Shu Cheong? Claim page and update insurance →
FAQ
Research and publications
81 papers · 12 most recent shown
Filter by paper topic
Topics come from medical classifications on these PubMed papers, not from the doctor's listed services.
- Two-year prognosis of mRNA vaccine-related myocarditis compared with historical conventional myocarditis: a population-based cohort study.Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases · 2026
- A 3-year prospective study to assess clinical characteristics and risk factors for exacerbations in patients with asthma-COPD overlap based on the GINA guideline compared with patients with asthma and COPD.Respiratory research · 2026
- A survey of respiratory physicians on investigating and managing tuberculous pleuritis.Scientific reports · 2026
- SARS-CoV-2 rebound and post-acute mortality and hospitalization among patients admitted with COVID-19: cohort study.Nature communications · 2025
- SARS-CoV-2 antibody responses in children exhibit higher FcR engagement and avidity than in adults.Nature communications · 2025
- Pharmacodynamic Effect of Different Dosage Regimes of Oseltamivir in Severe Influenza Patients Requiring Mechanical Ventilation: A Multicentre Randomised Controlled Trial.Influenza and other respiratory viruses · 2025
- Effectiveness of nirmatrelvir/ritonavir and molnupiravir in reducing the risk of short-term and long-term cardiovascular complications of COVID-19: a target trial emulation study.Nature communications · 2025
- Greater benefits of immediate nirmatrelvir-ritonavir initiation for post-COVID outcomes: a population-based retrospective cohort study.Nature communications · 2025
- Author Correction: Real-world COVID-19 vaccine effectiveness against the Omicron BA.2 variant in a SARS-CoV-2 infection-naive population.Nature medicine · 2024
- Quantitative and qualitative subgenomic RNA profiles of SARS-CoV-2 in respiratory samples: A comparison between Omicron BA.2 and non-VOC-D614G.Virologica Sinica · 2024
- Real-world COVID-19 vaccine effectiveness against the Omicron BA.2 variant in a SARS-CoV-2 infection-naive population.Nature medicine · 2023
- Impact of the Use of Oral Antiviral Agents on the Risk of Hospitalization in Community Coronavirus Disease 2019 Patients (COVID-19).Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2023
Publication data comes from PubMed / Europe PMC and is matched automatically by name and affiliation. Every entry links to the source.
Elsewhere on the web
These links are matched automatically by the doctor's name and are not confirmed by the doctor. Names repeat in Hong Kong — open a link to check.
For reference only. Not medical advice. Read full disclaimer